S-337395

Phase 2Small molecule

S-337395 is one of 3 small molecule programs targeting Respiratory Syncytial Virus Infections. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory Syncytial Virus InfectionsRecruiting

Respiratory Syncytial Virus InfectionsPhase 2

Recruiting

Competition

Competitive Landscape

6 competitors in Respiratory Syncytial Virus Infections

#DrugCompanyPhaseTrials

S-337395

Shionogi

Phase 2

1 2

AK0529

SShanghai Ark Biopharmaceutical Co., Ltd.

Phase 2

1 3

Ziresovir

SShanghai Ark Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Respiratory Syncytial Virus Infections

NCT07214571

Clinical

Trials by Indication[1]

Adult1 trial

A Study to Investigate Different Formulations of S-337395 in Healthy Adult Participants

Completed· Shionogi logo

Shionogi·Phase 1·NCT06270511·50 enrolled

Respiratory Syncytial Virus Infections1 trial

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus Who Are at High Risk of Progression to Severe Disease

Recruiting· Shionogi logo

Shionogi·Phase 2·NCT07214571·192 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for S-337395. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — S-337395 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for S-337395. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shionogi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Shionogi

S-337395

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Adult1 trial

Respiratory Syncytial Virus Infections1 trial

References

Drug Info

Quick Facts

Related News